Pattern and prognostic factors in patients with malignant ascites: a retrospective study

被引:270
作者
Ayantunde, A. A. [1 ]
Parsons, S. L. [1 ]
机构
[1] Univ Nottingham Hosp, Dept Surg, Nottingham City Hosp Campus, Nottingham NG5 1PB, England
关键词
cancers; chemotherapy; malignant ascites; paracentesis; prognotic factors; survival;
D O I
10.1093/annonc/mdl499
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Malignant ascites is a manifestation of end stage events in a variety of cancers and associated with a poor prognosis. We evaluated the pattern of cancers causing malignant ascites and factors affecting survival. Patients and methods: Patients coded with the International Classification of Diseases-9 coding system for malignant ascites over a 2-year period were reviewed. The clinicopathological data and patients' survival were compared among cancer groups. Results: There were 209 patients (140 females and 69 males), median age being 67 (30-98) years. The commonest cancer was ovarian followed by gastrointestinal (GI) cancers. Fifty-eight per cent of the patients had symptoms related to the ascites. Liver metastases were significantly commoner in the GI cancers (P = 0.0001). Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer. Paracentesis was given to 112, diuretics to 70 and chemotherapy to 103 patients. The median survival following diagnosis of ascites was 5.7 months. Ovarian cancer favoured longer survival while low serum albumin, low serum protein and liver metastases adversely affected survival. The independent prognostic factors for survival were cancer type, liver metastases and serum albumin. Conclusion: The identified independent prognostic factors should be used to select patients for multimodality therapy for adequate palliation.
引用
收藏
页码:945 / 949
页数:5
相关论文
共 18 条
[1]   ON THE TREATMENT AND PROGNOSIS OF MALIGNANT ASCITES - IS THE SURVIVAL-TIME DETERMINED WHEN THE ABDOMINAL PARACENTESIS IS NEEDED [J].
APPELQVIST, P ;
SILVO, J ;
SALMELA, L ;
KOSTIAINEN, S .
JOURNAL OF SURGICAL ONCOLOGY, 1982, 20 (04) :238-242
[2]  
Byrne AT, 2003, CLIN CANCER RES, V9, P5721
[3]  
EASSON A, 2005, J CLIN ONCOL S, V16, P6071
[4]   MALIGNANT ASCITES - CLINICAL AND EXPERIMENTAL-OBSERVATIONS [J].
GARRISON, RN ;
KAELIN, LD ;
HEUSER, LS ;
GALLOWAY, RH .
ANNALS OF SURGERY, 1986, 203 (06) :644-651
[5]   CONTROL OF MALIGNANT ASCITES WITH SPIRONOLACTONE [J].
GREENWAY, B ;
JOHNSON, PJ ;
WILLIAMS, R .
BRITISH JOURNAL OF SURGERY, 1982, 69 (08) :441-442
[6]   Immunotherapy of malignant ascites with trifunctional antibodies [J].
Heiss, MM ;
Ströhlein, MA ;
Jäger, M ;
Kimmig, R ;
Burges, A ;
Schoberth, A ;
Jauch, KW ;
Schildberg, FW ;
Lindhofer, H .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (03) :435-443
[7]  
Jaeger M, 2004, J CLIN ONCOL, V22, p164S
[8]   A survey of practice in management of malignant ascites [J].
Lee, CW ;
Bociek, G ;
Faught, W .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (02) :96-101
[9]  
Mackey J R, 1996, Can J Oncol, V6, P474
[10]   Intraperitioneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma [J].
Marmé, A ;
Strauss, G ;
Bastert, G ;
Grischke, EM ;
Moldenhauer, G .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (02) :183-189